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Regenerative medicineHuman platelet lysate (hPL) is a pool of growth factors and cytokines able to induce regeneration of dif-
ferent tissues. Despite its good potentiality as therapeutic tool for regenerative medicine applications,
hPL has been only moderately exploited in this field. A more widespread adoption has been limited
because of its rapid degradation at room temperature that decreases its functionality. Another limiting
factor for its extensive use is the difficulty of handling the hPL gels. In this work, silk fibroin-based
patches were developed to address several points: improving the handling of hPL, enabling their delivery
in a controlled manner and facilitating their storage by creating a device ready to use with expanded shelf
life. Patches of fibroin loaded with hPL were synthesized by electrospinning to take advantage of the
fibrous morphology. The release kinetics of the material was characterized and tuned through the control
of fibroin crystallinity. Cell viability assays, performed with primary human dermal fibroblasts, demon-
strated that fibroin is able to preserve the hPL biological activity and prolong its shelf-life. The strategy of
storing and preserving small active molecules within a naturally-derived, protein-based fibrous scaffold
was successfully implemented, leading to the design of a biocompatible device, which can potentially
simplify the storage and the application of the hPL on a human patient, undergoing medical procedures
such as surgery and wound care.
Statement of Significance
Human platelets lysate (hPL) is a mixture of growth factors and cytokines able to induce the regeneration
of damaged tissues. This study aims at enclosing hPL in a silk fibroin electrospun matrix to expand its
utilization. Silk fibroin showed the ability to preserve the hPL activity at temperature up to 60 C and
the manipulation of fibroin’s crystallinity provided a tool to modulate the hPL release kinetic. This entails
the possibility to fabricate the hPL silk fibroin patches in advance and store them, resulting in an easy and
fast accessibility and an expanded use of hPL for wound healing.
 2018 Acta Materialia Inc. Published by Elsevier Ltd. This is an open access article under the CCBY-NC-ND
license (http://creativecommons.org/licenses/by-nc-nd/4.0/).1. Introduction
Silk fibroin, a structural protein of the cocoons of the Bombyx
mori, is widely studied for biomedical applications, such as tissue
regeneration and drug delivery, because it is biocompatible,resorbable and can be fabricated in multiple formats [1–3]. The
extraction of fibroin from the cocoons, a process known as regen-
eration, results in an aqueous solution that can be used to fabricate
films, hydrogels, sponges, nanoparticles and fibers [1–8]. Silk
fibroin self-assembles from the water solution into an amorphous
state (called silk I) presenting a-helices, and a crystalline state
(called silk II) with high b-sheets content [2,9,10]. The b-sheets
characterizing silk II affect several of its physical and chemical
properties, such as mechanical strength and refractive index
[11,12]. Particularly interesting is the water stability provided by
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highly crystalline silk II does not dissolve in pure water [13]. The
transition from the amorphous state silk I to the crystalline silk II
can be favored by using alcohols or via water vapor annealing
[13–15]. The crystallization assisted by water vapor is slower,
more controlled and it allows to obtain different crystallinity
degrees by varying the treatment duration. Being a milder process,
water vapor annealing can be applied even when sensitive mole-
cules or cellular organelles are embedded in fibroin matrices
[13,16–28]. Crystallinity manipulation of fibroin was used as a pro-
cessing strategy to tune its biodegradability and to control the
release of drugs. In vitro enzymatic degradation assays, performed
on fibroin fibrous scaffolds, have shown a slower degradation rate
when the scaffold presented high crystallinity [8,29,30]. In vivo
studies confirmed the longer permanence of highly crystalline silk
fibroin implants [31]. The control on the degradation is especially
interesting in drug delivery applications, since controlling the rate
of degradation enables the prolonged and sustained delivery of
active factors during the entire course of the therapy. Investiga-
tions in vitro with highly crystalline silk fibroin matrices (>40%
crystallinity) showed a slower release compared to the amorphous
silk [20,32–35]. The ability of the silk fibroin in controlling the
release was found also in vivo using chemotherapeutic agents. They
were released in a sustained way and this kept their concentration
under toxic threshold [19,36]. On the top, such controlled delivery
can keep the overall drug concentration low within the patient’s
body, reducing the frequency of the treatment administration as
well [37]. Within the context of regenerative medicine, the sus-
tained release of growth factors from biodegradable polymeric
matrices showed an accelerated and improved wound healing
and a great potential for more complete cells differentiation in tis-
sue engineering [38–40]. Also for chronic wounds, keeping low the
concentration of growth factors and for longer time, can help their
healing [41,42].
Human platelets lysate (hPL) is a potential therapeutic tool
highly enriched with platelets-derived growth factors and cyto-
kines. Although there are no publications reporting the exact and
total content of single components of the hPL, many articles have
described some of the growth factors included: platelet-derived
growth factor B (PDGF-BB), fibroblasts growth factors (FGF), vascu-
lar endothelial growth factor (VEGF), epidermal growth factors
(EGF) and transforming growth factor-B 1 (TGF-b1) [43–45]. Such
growth factors are physiologically involved in regenerative and
healing processes. In vitro experiments have shown the hPL ability
to support every stage of the wound healing: favoring cells growth,
angiogenesis and stimulating the recruitment of white blood cells
[46–48]. In vivo experiments showed its ability to support bone
regeneration and the recovery of non-healing wounds [49,50].
hPL is commonly applied in the form of a gel, which can release
the platelets-derived factors [51]. Despite these promising results,
on-the-spot preparation, difficult handling, need of storage at low
temperature to preserve the activity of the factors are some of
the technical and practical limitations that still hinder the hPL
usage as therapeutic tool [52,53]. Therefore, there is a need of
designing a device that could conjugate the sustained release of
the allogenic hPL with an easier handling on a wound, while keep-
ing the hPL factors well-preserved. This would allow a more effec-
tive use of the hPL molecules in the wound care management.
The aim of this work is the creation of a device that is able to
take advantage of several properties of silk fibroin such to facilitate
and expand the use of hPL. In particular, silk fibroin provides a
matrix that can be processed in conditions that are compatible
with hPL (in water, at room temperature and at neutral pH) [3]
and that can be fabricated in micro and nanofibers using electro-
spinning [54,55]. In addition, the possibility to control the silk
fibroin crystallinity could be used as a mechanism to tune therelease kinetic [32,33,56]. Silk fibroin has shown the ability to sta-
bilize sensitive molecules and cell organelles [16–18,21–27,57],
and, building on this, the present work investigates how to exploit
this property to facilitate the use of hPL. Herein, the hPL was
encapsulated in silk fibroin electrospun fibers. The electrospun for-
mat was chosen because the porosity, granted by the micro and
nanofibers, facilitates both the absorption of exudate and an effi-
cient gas exchange, while supporting cell proliferation and migra-
tion. All the above mentioned features successfully mimic the
natural extracellular matrix, thus improving and sustaining the
healing process of the wounds [58–61].
Silk fibroin fibers with a high content of hPL were fabricated,
and their degradation and release kinetics were controlled via
manipulation of the fibroin crystallinity. The release kinetics of
the silk fibroin fibrous mats with different crystallinity degrees
were characterized tracking the release of albumin [62,63] using
an in vitro test that was developed to simulate in vivo degradation
conditions. Enzyme-linked immunosorbent assay (ELISA) was per-
formed to prove that the crystallinity of silk fibroin could control
the release kinetics of two of the hPL growth factors: PDGF and
TGF-b1. Furthermore, hPL released from silk fibroin fibers retained
its ability to induce and sustain the viability of primary adult
human dermal fibroblasts (HDFa) in vitro. Finally, the possibility
to use silk fibroin for the preservation of hPL biological activity
was proved even after thermal stress at 60 C [25,28], demonstrat-
ing the improvement of the shelf-life of hPL, granted by the fibroin
matrix. Such system can be proposed as a valid, easy-to-fabricate
and durable alternative to the platelet-rich plasma (PRP) gel in
the wound care management.2. Materials and methods
2.1. Materials
Sodium carbonate, sodium chloride, lithium bromide, poly
(ethylene oxide) (PEO, Mw = 1,000,000 g/mol), albumin conjugated
with fluorescein isothiocyanate (FITC-albumin), phosphate buffer
saline (PBS), Protease XIV (4 units/mg), paraformaldehyde (PFA)
and bovine serum albumin (BSA), Triton X-100 were purchased
from Sigma Aldrich (MO, USA). ELISA kit for the detection of
Human PDGF-BB was purchased from RayBiotech Inc (GA, USA);
ELISA kit for the detection of Human TGF-b1 was purchased from
Invitrogen (CA, USA). Human dermal fibroblast from adult (HDFa),
medium 106, low serum growth supplement kit, trypsin, trypsin
neutralizer, Alexa FluorTM 488 Phalloidin and ProLongTM Diamond
Antifade Mountant with DAPI were purchased from ThermoFisher
Scientific (MA, USA). Cell proliferation reagent WST-1 (2-(4-iodo
phenyl)-3-(4-nitophenyl)-5-(2,4-disulfophenyl)-2H-tetrazolium
monosodium salt) was purchased from Roche (Switzerland).
Finally, hPL was gently granted by Biorigen s.r.l. (Italy).2.2. Fibroin regeneration and hPL preparation
Fibroin was extracted from Bombyx mori cocoons according to
the protocol previously described by Rockwood et al. [3]. Firstly,
the cocoons were cut and boiled for 30 min in a water solution
of 0.023 M of Na2CO3; subsequently, the fibers were washed with
MilliQ (18.3 MX) water and dried. Degummed fibroin was solubi-
lized in an aqueous solution of 9.3 M of lithium bromide at 60 C
for 4 h and dialyzed in a tube with a MWCO of 3,500 kDa for 3 days
against MilliQ water. Finally, regenerated fibroin was centrifuged
twice at 9000 rpm, for 20 min at 4 C. To quantify the fibroin con-
centration, 1 mL of regenerated fibroin solution was left to dry
under an aspirating hood. Then, the dried film was weighted,
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centration was found to be in a range between 60 and 80 mg/mL.
hPL used in this work, provided by Biorigen s.r.l., was prepared
according to the method described by Zaky et al. [43]. Briefly, the
PRP obtained from buffy coat samples from the whole blood of
healthy donors, has undergone freeze–thaw cycles in order to
break the platelet membranes and to release their growth factors
content. The supernatant hPL recovered was freeze-dried. It con-
tained platelet growth factors with different size. To reduce or
avoid the variability from batch to batch, each single batch was
derived from 400 donors. hPL was standardized among batches,
by making sure that PDGF-BB and VEGF concentrations were con-
stant [44,45].
2.3. Fibers fabrication and water vapor treatment
To produce the fibers, fibroin 60 mg/mL solution was used. To
facilitate the electrospinning process and fabricate the fibers, PEO
powder 25% (w/wsilk) was added to a 60 mg/ml aqueous solution
of fibroin and stirred overnight. Generally, to electrospin silk
fibroin, PEO is added because it adjusts the viscosity of the regen-
erate silk fibroin, as reported in previous works [54,64–66]. Once a
homogeneous solution was obtained, FITC-albumin powder was
added such to obtain a concentration of 2% (w/wsilk). To add hPL,
a solution of it 7% (w/wsilk) was added to not diluted silk fibroin
solution. Therefore, hPL solution needs to have an enough volume
to dilute the silk fibroin solution at 60 mg/mL. The final concentra-
tion of the hPL in the electrospun fibers was 5% (w/w). The fibers
were electrospun at 20 C in a controlled humidity environment
(30%–40% relative humidity) with a syringe pump (NE-1000, New
Era Pump Systems, Inc., NY, USA) equipped with a blunt 19G nee-
dle, at a flow rate of 1 mLh1 (Fig. S1A). An aluminum, grounded
collector was placed at 20 cm from the needle, while a voltage of
18 kV was applied (EH40R2.5, Glassman High Voltage, Inc., US-
NJ, USA). In the case of the hPL loaded fibers, the following param-
eters were considered: a flow rate of 1.2 mLh1, a needle–collector
distance of 30 cm, and a voltage of 23 kV. These parameters were
optimized for the different compositions in order to have a contin-
uous electrospinning process and to produce beads-free fibers.
The crystallinity degree of the silk fibroin fibrous mats was
increased via water vapor annealing. The treatment was performed
in a vacuum oven (VO500EA, MLS, Italy) at 40 C and 85–90% of rel-
ative humidity. Different treatment times were used for the differ-
ent crystallization reported (Fig. S1B), ranging from 10 min to 6 h.
2.4. Fiber characterization
2.4.1. Morphology
Fiber morphology was characterized by scanning electron
microscopy (SEM) using a JEOL JSM-6490LA microscope (JEOL
Ltd., Japan), in high vacuum with an acceleration voltage of 15
kV. The samples were previously coated with a 10-nm-thick gold
layer with a Cressington 208HR high resolution sputter coater
(Cressington Scientific Instrument Ltd, U.K.). Size analysis was per-
formed with ImageJ software.
2.4.2. Drug encapsulation
The encapsulation of the hPL in the fibers was investigated
through the detection of the FITC-albumin, PDGF and TGF-b1.
FITC-albumin was observed by using a laser scanning confocal
microscope (A1R, Nikon, Japan). The lasers had wavelengths of
401–488 nm (Nikon, Japan). To evaluate the encapsulation of the
PDGF and TGF-b1, low crystalline fibrous mats were dissolved in
PBS 0.04 M pH 7.4 at 37 C for 24 h, to ensure a complete release
of hPL. Then, the releasing media were evaluated through the ELISAkits to quantify the PDGF and TGF-b1, according to the manufac-
turer’s instructions.
2.4.3. Fibroin crystallinity characterization
Characterization of the fiber crystallinity was performed by
Fourier transform infrared spectroscopy (FTIR). Samples were mea-
sured in Attenuated Total Reflectance (ATR) mode using MIRacle
ATR accessory (PIKE Technologies, WI, USA) coupled to a Fourier
Transform Infrared (FTIR) spectrometer (Equinox 70 FT-IR, Bruker,
MA, USA). All the spectra were acquired in a spectral range from
4000 to 600 cm1, with a scanning resolution of 4 cm1, accumu-
lating 64 scans.
The deconvolution of the fibroin amide I peak was performed as
reported previously by Guzman-Puyol et al. and Hu et al. [67,68].
The software was PeakFit 4.11 [67] and the wavenumber positions
of the different components were deduced by calculation of the
second-order derivative [68]. The fitting of the different contribu-
tions was performed using Gaussian-shaped peaks, using an equal
fixed width for all the considered peaks. The crystallinity content
was obtained from the ratio between the areas of the b-sheets
peaks and the total area of the amide I peak.
2.4.4. Drug release assessment
Electrospun silk fibroin unloaded (SF), loaded with FITC-
albumin (SF-alb), loaded with hPL (SF-hPL), and loaded both with
FITC-albumin and hPL (SF-alb-hPL) fibers, were weighted and
placed in a 24 well-plate with 1 mL of PBS 0.04 M at pH 7.4 and
with 6.25 mU of Protease XIV in 0.04 M PBS pH 7.4 at 37 C and
gently stirred on a tilting plate for 5 months. At given time points,
the total volume was taken out and substituted with fresh med-
ium. The amount of FITC-albumin was determined by correlating
the absorbance at 495 nm with a calibration curve measured by
using the same media, after subtraction of blank spectra obtained
by measuring the SF and SF-hPL samples. The measurements were
carried out using a UV–visible spectrophotometer (Cary 6000i-
Varian, CA, USA) from 450 nm to 550 nm.
To characterize the effect of the enzymatic degradation on the
samples, three SF-alb-hPL mats having different crystallinity
(22%, 35% and 45%) were incubated at 37 C for 1 month, either
with PBS or in the presence of PBS containing the enzyme
(6.25 mU/mgfibers). The medium was completely replaced every
day. At the end of the experiment, the mats were washed with
MilliQ water for 10 min five times, in order to remove traces of salt
and enzyme. After the final timepoint, the samples were rinsed,
dried and imaged by SEM.
The release kinetics of PDGF and TGF-b1 from SF-hPL mats with
different crystallinity (20%, 35% and 44%) were characterized by
quantifying the growth factors in the releasing medium. SF mats
were used as control. The experiment was carried out in a
protease-free buffer, in order to avoid the possible interference
between the protease and the antibodies used for the ELISA proce-
dure. Since the albumin results have shown that the sustained
release (after 24 h) is mainly caused by the proteolytic degradation
of the fibroin matrices, the release kinetic of the growth factors
was limited to the first 120 h. The fibers were incubated for 5 days
in PBS 0.04 M pH 7.4 at 37 C on a tilting plate. At given time point,
the total volume of the releasing mediumwas removed and substi-
tuted with fresh medium. The media, corresponding to each time
points, were stored at -20 C until they were analyzed by the ELISA.
The ELISAs were performed according to the manufacturer’s
instructions.
2.5. Biological activity of the released hPL
Primary human dermal fibroblasts from an adult donor (HDFa)
were seeded in medium 106, containing 2% (v/v) of fetal bovine
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mal growth factor, 3 ng/mL of basic fibroblast growth factor, and
10 lg/mL of heparin. The cells were split every 7 days and seeded
at a density of 4500 cells/cm2. Medium was changed every day.
To assess the retained activity of the released hPL, 20 mg of SF
and SF-hPL fibers, at 24% of crystallinity, were incubated, after ster-
ilization with UV treatment for 20 min for each side, in 4 mL of
serum-free culture medium for 24 h at 37 C. The low crystallinity
of the mats permitted the dissolution of the matrix and the com-
plete release of all the factors in 24 h. The size of silk fibroin mats
dissolved in the serum-free culture medium, was cut in order to
release 250 lg/mL of hPL in the media. This concentration was
chosen because, as observed in a dose–response experiment
(Fig. S8), it was found to be the minimum concentration able to
increase the viability of the HDFa. Twenty-four hours before the
treatment, cells were seeded with a density of 4500 cells/cm2 in
complete culture medium. The day after, some cells were used to
assess the viability before the treatment with the samples. This
reading was labeled time point zero. The rest were washed with
PBS and incubated according to the following conditions: SF
extracts, SF-hPL extracts, culture media containing the same hPL
amount released from the SF-hPL, and serum-free culture media
and complete culture media as controls. Cells viability was evalu-
ated through the analysis of the cell metabolism, thanks to a colori-
metric assay. WST-1 was directly added in culture medium with a
1:11 (v/v) ratio. After the addition of the WST-1, the cells were
incubated for 3 h, at 37 C with and 5% of CO2. The assay was per-
formed after 1, 3, and 5 days of treatment, acquiring the absor-
bance at 450 nm, through a multiwell plate reader (MultiskanTM
GO Microplate Spectrophotometer, ThermoFisher scientific, MA,
USA) and normalizing all the outcome signals with respect to the
absorbance value at the zero-time point.
2.6. Improvement of hPL shelf-life
With the aim of mimicking an aging process, an oven treatment
at 60 C was performed on SF and SF-hPL samples, lyophilized hPL
and on aliquots of plain and hPL-containing serum-free culture
media. Lyophilized hPL represents the common way for storage;
hPL dissolved in serum-free culture media mimics the common
‘‘device” use of hPL: the platelet gel; SF-hPL is the ready-to-use silk
fibroin-based device. 60 C were used because it is a temperature
at which labile molecules, like hPL proteins, are known to degrade
and because it is a temperature used in previous works to test the
improvement of stability granted by silk fibroin [25,28]. The elec-
trospun mats were cut to be 20 mg in mass, containing 1 mg of
hPL each and were dissolved, after the oven treatment and 20
min of UV sterilization cycle for each side, in 4 mL of serum-free
culture media for 24 h at 37 C, to release the encapsulated hPL
and prepare the extract for the following cell experiments. All
the electrospun samples were 24% crystalline, so they fully dis-
solved during the 24 h incubation. For the control samples, lyophi-
lized hPL was dissolved in the serum-free medium in order to have
the same concentration of the electrospun samples (250 lg/ml).
Three treatment time points were investigated: 24 h, 48 h and
72 h. HDFa cells were seeded onto 96-well plates at a density of
4500 cells/cm2 and let attached overnight. The next morning, cells
were treated with the prepared extracts from the thermally treated
samples above listed. WST-1 viability assay was performed after 5
days, acquiring the absorbance at 450 nm and normalizing all the
outcome signals with respect to the absorbance value of the nega-
tive control (mediumwithout serum and hPL). The residual activity
of the hPL was calculated from the ratio of the cell viability
observed in the case of the thermally treated mats and the cell via-
bility in the case of the untreated samples.2.7. Cells morphology
To evaluate the morphology of the cells directly seeded onto the
fibrous mats, electrospun silk fibroin fibers were collected on 14
mm coverslips and treated with water vapor for 10 min, as previ-
ously explained. After UV sterilization for 20 min, HDFa were
seeded on SF and SF-hPL matrices and observed under the confocal
microscope after 1, 3 and 5 days of growth. Cells were washed
twice with PBS, fixed with PFA 4% for 10 min, and treated with Tri-
ton X-100 0.1% in PBS for additional 10 min. Afterwards, the sam-
ples were incubated with a blocking solution of 1% BSA in PBS for
20 min and then stained with Alexa FluorTM 488 Phalloidin (diluted
1:40 in 1% BSA) for 20 min. All the steps were performed at room
temperature. Finally, the cells were mounted on glass slide with
ProLongTM Diamond Antifade Mountant containing DAPI for nuclear
staining and stored at 4 C.2.8. Statistical methods
The fibers size analysis was performed on three samples for
each fibrous formulation (SF, SF-alb, SF-hPL and SF-alb-hPL)
before and after the water vapor annealing. The average of size
measurements (n = 400) was obtained along the respective stan-
dard error.
Three samples of each fibrous sample and each condition (not
treated, treated for 10 min and treated for 6 h with water vapor)
were used for FITR analysis, acquiring 5 spectra from each of them,
which were averaged to obtain the final spectrum for the deconvo-
lution. The same samples (three for each crystallinity degree and
three for each fibers type) were used to investigate the release.
The average of the release from the triplicates was obtained with
the respective standard error. The quantification of the PDGF and
TGF-b1 released from the fibrous mats was performed by using
the respective ELISA kits. For the encapsulation analysis, 3 low
crystalline mats were used, while, for characterizing the release
kinetics, 3 different samples for each crystallinity were used. The
averages with the respective standards errors were obtained for
both the experiments. The cell viability assays were repeated 3
times for each fibrous sample. The average with the respective
standard error was obtained. For viability assays, the statistics
were performed through the analysis of variance (ANOVA), fol-
lowed by post-hoc Bonferroni correction. A value of p  0.05 was
considered statistically significant.3. Results
3.1. Fibers fabrication and characterization
In Fig. 1 and Fig. S2 electrospun mats SF, SF-alb, SF-hPL, SF-alb-
hPL are presented. The fibers were defect-free, showing a smooth
morphology. Their average diameter was measured to be 370 ± 3
nm, 330 ± 2 nm, 360 ± 3 nm, and 480 ± 2 nm, respectively. After
the water vapor treatment was performed, no statistically signifi-
cant change in the average diameter was observed, with dimen-
sions of 400 ± 4 nm, 370 ± 3 nm, 480 ± 4 nm, and 530 ± 8 nm,
respectively.
Although different electrospinning parameters were used, the
size and the morphology of the fibers did not significantly change
with the addition of the FITC-albumin or hPL. Up to 5% (w/w) of
hPL was loaded in the fibers, while above this amount, the process
became less continuous and reproducible.
After the water vapor treatment, the surface of the single fibers
resulted smooth, indicated that such treatment did not induce
modifications on their surface. On the other hand, it induced the
Fig. 1. SEM images of SF (a and b) and SF-hPL (d and e) fibers mats obtained by electrospinning. The fiber morphology is characterized before (a and d) and after (b and e) the
water vapor treatment. The insets show the corresponding size distributions. Photos of the obtained electrospun SF (c) and SF-hPL (d) fibrous mats.
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ciated with post treatment of fibroin fibers (Fig. 1) [69,70].
FITC-albumin was used as a tracer to characterize the release
kinetic from the electrospun fibers, since albumin is one of the ele-
ments of hPL (Fig. S3) [62,63]. The successful encapsulation was
verified with a confocal microscope, through the FITC fluorescence
(Fig. 2). The distribution of the fluorescence signal appeared
homogenous along the fibers and no differences were observed
when the hPL was added to the system (Fig. 2).
The encapsulation of PDGF and TGF-b1 in the electrospun fibers
was confirmed by ELISA: samples contained 128 ± 25 pg of PDGF
and 769 ± 85 pg of TGF-b1 per mg of fibrous mat.
Silk fibroin’s secondary structure (i.e. the formation of b–sheets
domains) is important to tailor the release kinetics from the elec-
trospun samples. To characterize it together with the modifications
induced by water vapor annealing, the amide I peak was analyzed
by FT-IR and reported in Fig. 3 [13]. The peak of the non-treated
fibrous mats was centered at 1651 cm1. After 10 min of water
vapor treatment, the spectra showed a change in the peak shape,
with a shoulder at 1628 cm1, while a further shift to 1624 cm1
was noticed after 6 h treatment. These changes can be associated
to an increase in the b-sheets formation, as reported previously
by Hu et al. [68].
The crystallinity degree was calculated for each sample through
the deconvolution of the amide I peak. As expected, non-treated
electrospun fibers showed a b-sheets content ranging from 21%
to 24%. On the other hand, fibers treated for 10 min presented a
crystallinity degree of 34–36%, while those undergoing water
vapor annealing for 6 h reached up to 44–46% of crystalline phase.3.2. Drug release assessment
3.2.1. Characterization of the drug release
To precisely assess the release kinetics for all the crystallinities
explored, a release medium with proteolytic enzymes was devel-
oped in order to simulate the in vivo enzymatic degradation. Pro-
tease XIV was used as proteolytic enzyme. Such Protease is
commonly used as enzyme for comparing the degradation proper-
ties of the silk fibroin [71,72]. The quantity of the protease was
selected, after testing several concentrations, to ensure that the
time of degradation of the fibroin in the release medium would
have the same kinetics reported in literature for the biodegrada-
tion in vivo. To select the protease concentration, 6.25 mU/mgfibers
and 250 mU/mgfibers were tested (Fig. S6). The 6.25 mU/mgfibers
was chosen because it resulted in a degradation time of 10 months,
comparable to previous data reported in literature on the silk
fibroin biodegradation in vivo [31,73].
Fig. 4 shows the release profiles of FITC-albumin from the
fibrous mats, with different crystallinity, over a period of 5 months.
The results are summarized in Table 1. The study was performed
on both SF-alb and SF-alb-hPL mats. In both cases, the fibers pre-
senting the lowest crystallinity were totally dissolved within 1 h
and all the encapsulated FITC-albumin was completely released.
During the initial burst, the samples with about 30% crystallinity
released 41 ± 2%–48 ± 2% of the loaded FITC-albumin. A strikingly
different behavior in this initial phase was observed for the sam-
ples with 45% of crystallinity, which released only 6 ± 0.2%–10 ±
0.7% of the total loaded FITC-albumin. After the initial burst, the
release continued with a slower rate for all the samples. For
Fig. 2. Confocal microscope images of SF-alb (a, b and c), and SF-alb-hPL (d, e and f).
370 C. Pignatelli et al. / Acta Biomaterialia 73 (2018) 365–376example, after 25 days SF-alb samples with 33% of crystallinity
showed a release of 90 ± 0.3%, while samples with crystallinity of
46% released 38 ± 1% of the total FITC-albumin (Fig. 4a). Similarly
(Fig. 4b), for the SF-alb-hPL samples, a release of 80 ± 2% was
observed from the mats with 35% of crystallinity, while a release
of 46 ± 1% was observed from the 44% crystalline mats. As shown
in Fig. S7, this sustained phase of the release was absent in all
the samples when the Protease XIV was not used during the exper-
iment, and a plateau at the end of the 24 h burst was observed.
In Fig. 5, SEM images show the fibers morphology of mats with
different crystallinity incubated with and without the enzyme for
1 month. The morphology of the fibers without the enzyme was
preserved, unlike those incubated with the enzyme, confirming
the destructive activity of the Protease XIV towards the fibroin.
The loss of the fibers’ morphology was higher when the crys-
tallinity was low. The effect of slower degradation of silk fibroin
by Protease XIV caused by the increased crystallinity was observed
also by Gil et al.[72]. They attributed this effect to the slower diffu-
sion of the enzyme in the amorphous fibroin phase. In fact, after its
crystallization, supramolecular interactions in the amorphous silk
fibroin increases, such to create a more organized structure, which
retards the passage of the enzyme through the crystalline domains.
The results in Fig. 5 are in agreement with the model they pro-
posed, confirming also that this crystalline dependent degradation
drove the second phase of the release.3.2.2. Characterization of the PDGF and TGF-b1 release
Since the hPL activity is principally due the growth factors, the
release kinetics of two of the main growth factors of the hPL, PDGF
and TGF-b1, were evaluated. The experiments were performed on
three mats with different crystallinity, to investigate how the dif-
ferent crystallinities influence the release of these growth factors.Fig. 7a and b show the burst release of the PDGF and TGF-b1
respectively. The results are summarized in Table 2. When the
fibrous mats had the lowest crystallinity, 20%, the PDGF and TGF-
b1 were completely released due to the total dissolution of the
fibers. When the crystallinity of the fibrous mats was 35%, the
PDGF released was 78 ± 9% after 24 h, while when the crystallinity
was 44%, the PDGF released was 62 ± 3%, after 24 h. The TGF-b1
released was 40 ± 12% after 24 h, when the mat was 35% crys-
talline, while, when the mat was 44% crystalline, it was 12 ± 2%
after 24 h. These results suggested that in the initial burst (24 h),
as for the albumin (Fig. 7c), the release kinetics of the PDGF and
TGF-b1 can be tuned by controlling the crystallinity of fibroin. In
addition, the release kinetic of the PDGF resulted faster than the
TGF-b1 and the albumin ones.3.3. Biological activity of released hPL
To verify the activity of the hPL encapsulated in the fibers, low
crystalline SF and SF-hPL samples were incubated in serum-free
culture media, for 24 h. The Protease XIV was not used, since the
sample completely dissolved in the media thanks to their low crys-
tallinity. Fig. 8a shows the viability of HDFa cells treated with
media containing the dissolved fibers. As control samples, cells
were seeded in serum-free medium (labeled as negative control),
or in serum-free medium in which lyophilized hPL was dissolved
(labeled hPL), or in media with serum (labeled FBS). The amount
of lyophilized hPL in the control was the same as the one released
from SF-hPL fibers (250 lg/mL). This concentration, from the
results showed in Fig. S8, resulted sufficient to observe an increase
in HDFa viability. The absorbance values of all the days were nor-
malized on the absorbance values relative to the zero-time point.
After the first day of treatment, cells cultivated in media with
Fig. 3. Deconvoluted FT-IR spectra of the amide I band of non-treated fibers (a),
fibers treated for 10 min (b), and fibers treated for 6 h (c). The crystallinity content
for these samples are 21%, 34%, and 45%, respectively. SC = side chains; B = b-sheets;
R = random coils; A = a-helices; T = turns.
Fig. 4. FITC-albumin release kinetics: (a) SF-alb and (b) SF-alb-hPL electrospun
fibers. The percentages indicate the crystallinity of the fibrous mats. The release
medium contained Protease XIV, to simulate the in-vivo degradation.
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ity (p > 0.05). They resulted two-fold higher than the negative
control (p < 0.0001). This higher viability can be associated to the
cell proliferation induced by the hPL, as reported in previous work
[74]. These trends were confirmed after three and five days. Silk
fibroin produced no effects on the cells viability, confirming that
the increase of the cell viability is due the hPL released from the
fibroin fibers. Therefore, these results proved that the growth
factors released from the SF-hPL were still active and that they
could increase and sustain the cells viability of the HDFa cells for
up to 5 days.3.4. Cells morphology
To evaluate the role of the hPL in cell adhesion and morphology,
HDFa were seeded on the SF and SF-hPL mats for 1, 3 and 5 days
(Fig. 8b, c and S10). Intermediate crystalline fibrous mats (about
30% crystallinity) were used, in order to avoid their dissolution
and allow the cells to attach. As visible from Fig. 8b and c, the cells
attached onto SF mats after 5 days, mostly showed a rounded mor-
phology, while, when seeded onto SF-hPL fibers, the cells appeared
more elongated. Moreover, the presence of the hPL in the fibers
seemed to accelerate cellular adhesion processes. Control samples
on flat films with the same composition of the SF-hPL fibers, shownin Fig. S11, confirmed that the elongated morphology was caused
by the hPL encapsulated in the fibers.3.5. hPL shelf-life
To test if the activity of hPL growth factors can be preserved via
encapsulation in silk fibroin fibers, an accelerated stability test was
performed, inducing a thermal stress at 60 C [25,28]. Three condi-
tions were tested: lyophilized hPL, hPL dissolved in serum-free
medium and SF-hPL. As shown in Fig. 9, the activity of the free
hPL in solution was reduced at 66 ± 3% after 1 day of thermal treat-
ment and it decreased to 41 ± 2% after 3 days. The lyophilized hPL,
showed an activity of 76 ± 2% after three days of treatment. On the
other hand, the activity of the hPL released from the SF-hPL mats,
thermally treated for three days, was 88 ± 6%. It resulted statisti-
cally more active than the lyophilized hPL (p < 0.05) and the dis-
solved hPL (p < 0.0001), demonstrating the ability of silk fibroin
to preserve the functionality of the encapsulated molecules even
at temperatures that are expected to denature the labile hPL
components.
Fig. 5. SEM images of SF-alb-hPL mats with different crystallinity. Micrographs a, b and c depict fiber morphology for the mats with crystallinity of 22%, 35% and 45%
respectively, incubated in PBS for 1month. Micrographs d, e and f, show the resulting morphology of mats at equal crystallinity after incubation with Protease XIV
(6.25 mU/mgfibers).
Table 1
Summary of the release kinetics of FITC-albumin from SF-alb and SF-alb-hPL samples reported in Fig. 4.
Samples Crystallinity Burst release 0–24 h Sustained release 1–25 d Sustained release 26–146 d
SF-alb 23% 98 ± 2% – –
33% 41 ± 2% 90 ± 0.3% 99 ± 0.5%
46% 6 ± 0.2% 38 ± 1% 62 ± 1%
SF-alb-hPL 21% 99 ± 0.4% – –
35% 48 ± 2% 80 ± 2% 90 ± 2%
44% 10 ± 0.7% 46 ± 1% 74 ± 2%
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Silk fibroin electrospun fibers, were fabricated from the aque-
ous solution of fibroin, using PEO to facilitate the process, following
a strategy adopted in previous works [54,64–66]. This procedure
proved to be effective even for high loading of hPL. To have well-
formed submicron fibers, the parameters were adjusted to account
for the presence of meta-stable, complex composition of hPL. Since
albumin is a component of the hPL (as reported in literature and
confirmed in Fig. S3), the fluorescently tagged FITC-albumin was
encapsulated in the fibers and used as a tracker because of its
easier detection [63]. The homogeneous encapsulation of FITC-
albumin in SF-alb and SF-alb-hPL suggested a homogeneous load-
ing of hPL in the electrospun mats as well. In addition, the confir-
mation of the hPL encapsulation was demonstrated with the ELISA
analysis, which detected the PDGF and TGF-b1, and by the in vitro
experiments in results Section 3.3.
Several studies have shown that the mechanism for degradation
of silk fibroin depends on its crystallinity [71]. At low crystallinity
(<20%), a fast dissolution is the main pathway for degradation,
while, when the crystalline phase is increased (>40%), the main
pathway accountable for the degradation is the proteolysis, other-
wise the dissolution only accounts for 4% of the mass [29,31–33,71–73,75]. The material’s integrity is intertwined with the release
of drugs from silk fibroin matrices: for amorphous fibroin, the
release was dictated by the dissolution of the material, while for
fibroin with high b-sheets content the kinetic depended on the
molecular weight of the drug and on the degradation of the silk
matrix. A schematic depicting these two mechanisms is reported
in Fig. 6. Through the water vapor treatment, a fine control on
the fibroin crystallinity was ensured, enabling a tool to tune the
release time of FITC-albumin, PDGF and TGF-b1 from the electro-
spun samples (SF-alb, SF-alb-hPL and SF-hPL) over a large range
of time scales. In fact, the results reported in Fig. 4, Fig. 7 and
Fig. S7 suggested that, the release kinetics of albumin, PDGF and
TGF-b1 were mostly dictated by the fibroin matrix and its crys-
tallinity degree. In previous works by Hines and Kaplan [32,33],
the release of small molecules from silk fibroin films was charac-
terized. Two sequential steps were hypothesized: an initial release
controlled by the diffusion of the molecules within the fibroin
matrix, followed by a second step in which the release from the silk
fibroin film was supposed to be controlled by the degradation of
the polymeric matrix. In addition, by studying the effect of molec-
ular weight, they showed that the diffusion of small molecules was
less affected by the crystallinity than the diffusion of higher molec-
ular weight ones. The results of this study support the proposed
Fig. 6. Proposed mechanism of controlled release from silk fibroin fibrous mats, considering the different silk fibroin crystallinity degree and the presence of the enzymatic
activity. Low crystalline samples completely dissolved during the burst release, while the highly crystalline samples featured a reduced release due to the presence of the
crystalline domains which impaired the diffusion of the FITC-albumin molecules. After the burst release, for the highly crystalline mats, when the enzyme degradation is not
present, the molecules would remain entrapped in the fibroin matrix, whereas, by adding an enzyme, the degradation of the crystalline domain induces the release of the
FITCalbumin and the other molecules embedded in it. Therefore, crystallinity also appeared to affect this second release step. In fact, by increasing the crystallinity, the
supramolecular interactions in the amorphous silk fibroin increases, such to create a more organized structure, which retards the passage of the enzyme through the
crystalline domains. This leads to a slower degradation rate of the fibers during the release process, inducing a crystallinity-dependent release.
Table 2
Summary of the burst release of the PDGF, TGF-b1 and FITC-albumin reported Fig. 7.
The data were obtained in the absence of the enzyme.
Crystallinity PDGF TGF-b1 FITC-albumin
20% 97 ± 4% 90 ± 0.1% 98 ± 2%
35% 78 ± 9% 40 ± 12% 40 ± 4%
44% 62 ± 3% 12 ± 2% 10 ± 0.1%
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silk fibroin matrix plays an important role in determining the
release: as shown in Fig. S7, in the absence of a proteolytic enzyme,
the release was inhibited after the first 24 h. The degradation-
dependent release, hypothesized by Hines and Kaplan, is shownFig. 7. Release kinetics of the first 120 h of (a) PDGF, (b) TGF-b1 and (c) FITC-albumin from
without the enzyme. Particularly, the data of PDGF and TGF-b1 were obtained by usin
calculating the concentration released.in this work for the first time to be able to support a sustained
release. This degradation-dependent release was more relevant
for higher molecular weight molecules like TGF-b1 and albumin
but, to a minor degree, it was observed for the smaller PDGF as
well. In fact, the mechanism for the release was different for the
two growth factors: the burst release was higher for the PDGF,
indicating a more diffusion-driven release, while TGF-b1 showed
a behavior similar to that was observed for albumin, suggesting a
release dominated by the silk fibroin degradation. It is worth not-
ing that for PDGF, even if the diffusion is the main mechanism for
release, a significant portion (40%) remains entrapped in the matrix
at high silk fibroin crystallinity.
Nultsch et al. [56] showed that the release kinetic can be
affected by the molecules’ charge (or their isoelectric points, IP).fibrous samples at three different crystallinities. The experiments were performed
g the ELISA kits, while the ones of the FITC-albumin by using the absorbance for
Fig. 8. a) Viability of HDFa cells treated either with 250 lg/mL of hPL or with the extracts of SF and SF-hPL fibers. The values were normalized with respect to the absorbance
value of the cells before the treatments, which is showed as a dashed line in the graph; the cells in presence of the hPL from SF-hPL (SF-hPL) showed an increase in viability
similar to those grown with hPL dissolved in serum-free medium (hPL) (p > 0.05), during all the experiment; SF-hPL cells had a viability statistically higher than those
cultivated with SF extracts (p < 0.0001) during the five days; b) and c) Confocal images of HDFa cells seeded onto the SF and SF-hPL fibrous mats at 5 days of culture. F-actin is
stained with the Alexa-fluor phalloidin (green), while nuclei are stained with DAPI (blue). (For interpretation of the references to colour in this figure legend, the reader is
referred to the web version of this article.)
Table 3
FITC-albumin releasing rate from silk fibroin fibrous mats at different crystallinity.
The rates derive from the graph in Fig. 4.







Burst 24 h (%/h) 0.4 2 4
1–7 day (%/d) 1 2 –




Fig. 9. hPL activity of dissolved hPL, lyophilized hPL and hPL released from SF-hPL
matrices after the accelerated stability test. The activity of the hPL released from the
fibers after 3 days of thermal treatment had an activity statistically higher activity
than the lyophilized hPL (p < 0.05) and dissolved hPL (p < 0.0001).
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(IP = 9.3) and TGF-b1 (IP = 8.83) [76–79], the effect of charge was
not evident.
Thus, for hPL proteins with molecular weight similar to albu-
min, the release kinetic during the burst phase (0–24 h), the degra-
dation phase (24 h to 7 days) and the sustained degradation (8
days to exhaustion) are reported in Table 3. The rates have been
obtained from the graph in Fig. 4. These results showed how the
release of drugs can be tuned from few hours for the low crys-
talline silk fibroin (<24% crystallinity), up to 20 days for the inter-
mediate crystalline samples (between 25% and 35% crystallinity),
and a sustained release for up to 100 days for the highly crystalline
silk fibroin (>36% crystallinity).
Viability assays performed on the HDFa cells, reported in Fig. 8a,
demonstrated that the labile growth factors and cytokines present
in hPL are still active after all the fabrication steps. Moreover, HDFa
cells seeded onto SF-hPL fibers were able to successfully attach on
the matrix, acquiring an elongated morphology which was kept by
the cells during all the 5 days of growth (Fig. 8b, c and S10). As
shown by Barsotti et al. [46] and Anitua et al. [74], platelets-derived proteins induced similar changes on dermal fibroblast. This
morphology was hypothesized to be associated to cell polarization,
a complex process involved in cell migration and wound closure
[47].
The preservation of the hPL growth factors activity is of crucial
importance not only in the short term of usage, when applied as
wound management device, but also in the long term of storage
after the fabrication. Nowadays, the general usage of the
platelets-derived factors is in a gel form, which needs to be pre-
pared immediately before the treatment [51]. This procedure is
time consuming, difficult and only accessible to qualified opera-
tors. Thus, the possibility of having a hPL-encapsulated device as
a ready-to-use patch should simplify the operations. Given the
meta-stability of the growth factors, an improved device should
be able to protect and preserve the biological activity of the hPL
proteins, in the long term. Fibroin is known to be able to preserve
growth factors and enzymes, and to stabilize blood [16–18,21–27].
As highlighted in Fig. 9, hPL released from SF-hPL patches was able
to increase cell viability after 3 days of thermal stress, demonstrat-
ing the protective role of the fibroin towards the hPL proteins.
These results show that the SF-hPL device, in its ready-to-use form,
has a stability that is even better than the lyophilized form of hPL.
This entails the possibility that SF-hPL devices could be prepared in
advance, simplifying their conservation and facilitating their use.5. Conclusions
The work has demonstrated that electrospun silk fibroin fibers
encapsulating the hPL can be fabricated with high loading
efficiency: 5% (w/w) of the total mass of the fibers. In addition,
the study has shown that silk fibroin can encapsulate hPL and that
C. Pignatelli et al. / Acta Biomaterialia 73 (2018) 365–376 375the release can be modulated by controlling the silk fibroin’s crys-
tallinity using a simple and mild water vapor treatment. The tun-
ability of the release, mediated by the crystallinity, was
demonstrated and, for the first time, characterized for such long
kinetics. Surprisingly, the crystallinity was able to tune the release
of albumin in a range spanning from few hours to almost 3 months.
Furthermore, the hPL released from the fibers retained its biologi-
cal activity, sustaining the HDFa cell growth in vitro for up to 5
days. Interestingly, hPL-treated cells appeared to acquire a more
polarized morphology, typical of migrating cells that are involved
in the wound closure. Finally, the work demonstrated that silk
fibroin has a positive protective effect on the hPL, improving their
stability at high temperature, suggesting that the electrospun
device would have an improved shelf life granted by the silk fibroin
matrix.
The proposed engineered fibers could facilitate the use of hPL
for wound healing and in medical procedures in which hPL gels
are currently used. Electrospun patches are readily applicable to
the wound site, similarly to a gauze, could have a pre-
determined release kinetic and could be prepared and store as
ready-to-use devices thanks to the preservation of the hPL activity
and the prolonged shelf life granted by the silk matrix.
A more precise knowledge of the growth factors’ release and
their biological activity in vitro and in vivo, could lead to the exploit
of the facile usage, tunable degradation and sustained release in
different applications from wound healing to regenerative
medicine.
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